Nav: Home

Watch a 3D-engineered human heart tissue beat

November 08, 2018

Researchers have developed a way to grow human heart tissue that can serve as a model for the upper chambers of the heart, known as the atria. The tissue, derived from human induced pluripotent stem cells (hiPCSs), beats, expresses genes, and responds to drugs in a manner similar to a real human atrium. The model, described November 8 in the journal Stem Cell Reports, may be useful for evaluating disease mechanisms and drugs for atrial fibrillation--the most common type of arrhythmia.

In contrast to standard 2D culture, the stem-cell-derived cardiomyocytes were cultured in a way that they formed 3D beating heart tissue resembling atrial heart muscle. Specifically, the cells showed atrial-like gene expression, contractile force, contraction and relaxation kinetics, electrophysiological properties, and pharmacological responses to atrial-selective drugs. According to the authors, the engineered heart tissue could serve as a model of the human atrium for both mechanistic studies of atrial fibrillation and for preclinical drug screening.

"This is the first time that human atrial heart tissue has been generated in vitro from a principally unlimited source of hiPSCs," says first author Marta Lemme of the University Medical Center Hamburg-Eppendorf. "This could be useful both for academic laboratories and the pharmaceutical industry, because to test potential new drugs, we need to generate an in vitro model of atrial fibrillation. And the first step in that is to obtain cells that resemble human atrial cardiomyocytes," Lemme says.

Lemme and senior study author Thomas Eschenhagen of the University Medical Center Hamburg-Eppendorf set out to achieve this goal by generating atrial-like cardiomyocytes from hiPSCs using a vitamin A metabolite called all-trans retinoic acid. This technique involves genetically reprogramming blood or skin cells taken from human donors to an embryonic stem-cell-like state and then treating these immature cells with all-trans retinoic acid to convert them into atrial-like cardiomyocytes.

"But the novelty of this study is the combination of hiPSC differentiation into atrial cardiomyocytes with a 3D environment," Lemme says. "In fact, we showed that the 3D environment favors the differentiation toward an atrial phenotype compared to standard 2D culture. A particular value of our study is the direct comparison of our 3D engineered heart tissue with native human atrial tissue obtained from patients on a molecular and functional level."

More than 33 million people worldwide suffer from atrial fibrillation, and the prevalence is rising. Uncoordinated high-frequency contractions in the atria increase the risk for blood clots, stroke, and heart failure. Unfortunately, existing treatments such as antiarrhythmic drugs have limited efficacy and can cause adverse effects. Moreover, the development of new drugs has been hindered by the difficulty in isolating and maintaining human atrial cardiomyocytes, or heart muscle cells. Animal models have limited predictive power because they do not accurately represent the physiology of human cardiomyocytes.

"These atrial muscle strips represent a great opportunity to model atrial fibrillation in the dish and test drugs," Lemme says. "Nevertheless, improvements can still be made to reach even higher similarity with the human atrial tissue. For us, the next step is to test various means to induce arrhythmias, study mechanisms of electrical remodeling of atrial fibrillation and test new potential drugs."
-end-
This research was supported by AFib-TrainNet, the National Research, Development and Innovation Office, the German Ministry of Education and Research (BMBF) and German Centre for Cardiovascular Research, the European Research Council (ERC AG IndivuHeart), the Deutsche Forschungsgemeinschaft, and Leducq Fondation. Thomas Eschenhagen and Arne Hansen are co-founders of EHT Technologies, Hamburg. Godfrey Smith is a founder and executive of Clyde Biosciences Ltd (UK).

Stem Cell Reports, Lemme et al.: "Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium" https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(18)30431-4

Stem Cell Reports, published by Cell Press for the International Society for Stem Cell Research (@ISSCR), is a monthly open-access forum communicating basic discoveries in stem cell research, in addition to translational and clinical studies. The journal focuses on shorter, single-point manuscripts that report original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. Visit http://www.cell.com/stem-cell-reports. To receive Cell Press media alerts, please contact press@cell.com.

Cell Press

Related Atrial Fibrillation Articles:

Sleep apnea may increase atrial fibrillation risk
Obstructive sleep apnea (OSA) may increase the risk of developing atrial fibrillation (AF), according to new research presented at the ATS 2017 International Conference.
New study identifies biomarker that may indicate risk of atrial fibrillation
Researchers have identified a microRNA biomarker that demonstrates a strong association with the incidence of atrial fibrillation, the most common abnormal heart rhythm.
More women with atrial fibrillation die after ER discharge than men
A new study from the University of Alberta adds to the growing evidence that women with cardiovascular disease may receive different health care from men -- and experience worse outcomes.
Big women have nearly threefold greater risk of atrial fibrillation
Big women have a nearly threefold greater risk of atrial fibrillation than small women, according to research presented today at EuroPrevent 2017.
Most atrial fibrillation patients don't get preventive drug before stroke
More than 80 percent of stroke patients with a history of atrial fibrillation either received not enough or no anticoagulation therapy prior to having a stroke, despite the drugs' proven record of reducing stroke risk, according to a Duke Clinical Research Institute study.
More than half of atrial fibrillation patients become asymptomatic after catheter ablation
More than half of patients with atrial fibrillation become asymptomatic after catheter ablation, reports the largest study of the procedure published today in European Heart Journal.
Medication adherence a problem in atrial fibrillation patients
Anticoagulant therapy is important for stroke prevention in people with atrial fibrillation, but a new study shows many people don't stick with it.
Atrial fibrillation patients are at increased risk of dementia, regardless of anticoagulation use
Atrial fibrillation patients who use the drug, warfarin, to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.
iPhone camera application may detect atrial fibrillation
A smartphone application made it possible to use the iPhone camera to detect atrial fibrillation via facial signals and without physical contact, according to a preliminary study presented at the American Heart Association's Scientific Sessions 2016.
Study reports progress in preventing bleeding in atrial fibrillation
A new study led by clinician-researchers at Beth Israel Deaconess Medical Center testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures has shown that therapies combining the anticoagulant drug rivaroxaban with either single or dual anti-platelet therapy were more effective in preventing bleeding complications than the current standard of care.

Related Atrial Fibrillation Reading:

Beat Your A-Fib: The Essential Guide to Finding Your Cure: Written in everyday language for patients with Atrial Fibrillation
by Steve S Ryan PhD (Author), Patti J Ryan (Contributor)

Surgical Treatment of Atrial Fibrillation: A Comprehensive Guide to Performing the Cox Maze IV Procedure
by Jonathan Philpott MD (Author), Christian Zemlin (Author), Ralph J. Damiano (Author)

Lone Atrial Fibrillation Towards a Cure
by Hans R. Larsen (Author), Dr. Patrick Chambers MD (Contributor), Philippe Coumel MD FESC (Contributor)

Conquer Your A-Fib: How To Beat Atrial Fibrillation
by Lisa M. White (Author)

A Life on Hold: Crossing Paths with Atrial Fibrillation
by Kevin J Kauffman (Author)

Atrial Fibrillation: A Multidisciplinary Approach to Improving Patient Outcomes (Cardiovascular Team Approach)
by N. A. Mark Estes III (Author), N. A. Mark Estes III (Editor), Albert L. Waldo (Editor), Joseph Alpert (Editor), Lynne T. Braun (Editor), Gerald Fletcher (Editor), Barbara Fletcher (Editor)

Atrial Fibrillation: Remineralize Your Heart

Atrial Fibrillation: How to Use Diet to Manage Atrial Fibrillations, Remineralize Your Heart, and Control Your Heart Rhythm
by Applied Knowledge

In a Heartbeat: The Ups and Downs of Life with Atrial Fib
by Rosalie Ungar (Author)

Atrial fibrillation e-chart: Quick reference guide
by HC-HealthComm

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Where Joy Hides
When we focus so much on achievement and success, it's easy to lose sight of joy. This hour, TED speakers search for joy in unexpected places, and explain why it's crucial to a fulfilling life. Speakers include inventor Simone Giertz, designer Ingrid Fetell Lee, journalist David Baron, and musician Meklit Hadero.
Now Playing: Science for the People

#500 500th Episode
This week we turn 500! To celebrate, we're taking the opportunity to go off format, talk about the journey through 500 episodes, and answer questions from our lovely listeners. Join hosts Bethany Brookshire and Rachelle Saunders as we talk through the show's history, how we've grown and changed, and what we love about the Science for the People. Here's to 500 more episodes!